# USBC, Inc.: Form 10-Q for the period ended Mar 31, 2013

- Company: [USBC, Inc.](/companies/usbc.md) (CIK 1074828)
- Form: 10-Q
- Filed: 2013-05-10
- Accepted by EDGAR: May 10, 2013, 16:21 ET
- Period: 2013-03-31
- Accession: 0001199835-13-000231
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1074828/000119983513000231/visualant_10q-15510.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1074828/000119983513000231/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2013-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Cost of revenue | 3 months, 2013-01-01 to 2013-03-31 | $1.6m | us-gaap:CostOfServices |
| Cost of revenue | 6 months, 2012-10-01 to 2013-03-31 | $3.2m | us-gaap:CostOfServices |
| Gross profit | 3 months, 2013-01-01 to 2013-03-31 | $575.0k | us-gaap:GrossProfit |
| Gross profit | 6 months, 2012-10-01 to 2013-03-31 | $1.1m | us-gaap:GrossProfit |
| Research and development | 3 months, 2013-01-01 to 2013-03-31 | $212.4k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2012-10-01 to 2013-03-31 | $378.8k | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2013-01-01 to 2013-03-31 | $1.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2012-10-01 to 2013-03-31 | $2.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2013-01-01 to 2013-03-31 | −$1.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2012-10-01 to 2013-03-31 | −$1.8m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months, 2013-01-01 to 2013-03-31 | $75.8k | us-gaap:InterestExpense |
| Interest expense | 6 months, 2012-10-01 to 2013-03-31 | $116.0k | us-gaap:InterestExpense |
| Net income | 3 months, 2013-01-01 to 2013-03-31 | −$2.3m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2012-10-01 to 2013-03-31 | −$3.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2013-01-01 to 2013-03-31 | −$0.02 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months, 2012-10-01 to 2013-03-31 | −$0.03 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months, 2012-10-01 to 2013-03-31 | −$1.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2012-10-01 to 2013-03-31 | $14.7k | us-gaap:PaymentsToAcquireProductiveAssets |
| Cash and equivalents | at 2013-03-31 | $14.7k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2013-03-31 | $1.8m | us-gaap:AssetsCurrent |
| Total assets | at 2013-03-31 | $4.1m | us-gaap:Assets |
| Current liabilities | at 2013-03-31 | $5.5m | us-gaap:LiabilitiesCurrent |
| Long-term debt | at 2013-03-31 | $2.9k | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | at 2013-03-31 | −$1.4m | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 20,167 characters.

Forward-looking statements in this report reflect the good-faith judgment of our management and the statements are based on facts and factors as we currently know them. Forward-looking statements are subject to risks and uncertainties and actual results and outcomes may differ materially from the results and outcomes discussed in the forward-looking statements. Factors that could cause or contribute to such differences in results and outcomes include, but are not limited to, those discussed below as well as those discussed elsewhere in this report (including in Part II, Item 1A (Risk Factors)). Readers are urged not to place undue reliance on these forward-looking statements because they speak only as of the date of this report. We undertake no obligation to revise or update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this report.

We have developed a unique patented Spectral Pattern Matching we have trademarked under the name ‘ChromaID™’. This technology directs structured light onto a physical substance to capture a unique spectral signature. When matched against existing databases, the ChromaID Profile can identify, detect, or diagnose markers invisible to the human eye. ChromaID scanners can be integrated into a variety of mobile or fixed-mount form factors, making it possible to effectively conduct analyses in the field that could only previously be performed by large and expensive lab-based tests.

We have a Joint Development Agreement through December 31, 2013 with Sumitomo Precision Products Co., Ltd. ("SPP"), which focuses on the commercialization of the ChromaID technology and a License Agreement providing SPP with an exclusive license of the ChromaID technology in identified Asian territories. For more information, visit: http://www.visualant.net.

SPP is publicly traded in Japan and has operations in Japan, United States, China, United Kingdom, Canada and other parts of the world. Additional information on SPP is available at http://www.spp.co.jp/English/index2-e.html.

On September 6, 2011, we announced that the Company was issued US Patent No. 7,996,173, entitled “Method, Apparatus and Article to Facilitate Distributed Evaluation of Objects Using Electromagnetic Energy,” by the United States Office of Patents and Trademarks.

On January 19, 2012, we announced that the Company was issued US Patent No. 8,081,304, entitled “Method, Apparatus and Article to Facilitate Evaluation of Objects Using Electromagnetic Energy” by the United States Office of Patents and Trademarks.

On March 20, 2012, we announced that the Company was issued US Patent No. 8,076,630, entitled “System and Method of Evaluating an Object Using Electromagnetic Energy” by the United States Office of Patents and Trademarks.

On November 1, 2012, we announced that the Company was issued US Patent No. 8,285,510 entitled “System and Method of Evaluating an Object Using Electromagnetic Energy” by the United States Office of Patents and Trademarks.

On April 1, 2013, the Company announced that it was issued US Patent No. 8,368,878 B2 and is entitled “Method, Apparatus and Article To Facilitate Evaluation of Object Using Electromagnetic Energy by the United States Office of Patents and Trademarks.

We are pursuing an aggressive patent strategy to expand our unique intellectual property in the United States and Japan.

Through our wholly owned subsidiary, TransTech, based in Aurora, Oregon, we provide value added security and authentication solutions to corporate and government security and law enforcement markets throughout the United States.

On February 6, 2013, the Company’s ChromaID technology won the Green Photonics section of the 2013 Annual Prism Awards at SPIE Photonics West 2013. The award honors solutions that generate or conserve energy, cut emissions, reduce pollution, and yield sustainable outputs.

### THE COMPANY’S COMMON STOCK

Our common stock trades on the OTCBB Exchange under the symbol “VSUL.”

### KEY MARKET PRIORITIES

Currently, our key market priorities are, among other things, to:

### Develop Markets and Customers.

Develop markets and customers who have a need for discovery, verification and authentication of flat surface products such as medical diagnostics, Pharmaceuticals, paint, papers, inks, plastics and magnetic tapes for security cards and similar products.

The specific vertical markets we are pursuing are major commercial paint manufacturers, pharmaceutical equipment manufacturers, process control companies, currency paper and ink manufacturers, security card manufacturers and card reader and scanner manufacturers. Our partner SPP is pursuing opportunities in the display manufacturing vertical, including the food processing and electronic gaming areas.

Future market opportunities will include powder analysis for law enforcement applications and pharmaceutical company applications for verification of illegal substances and verification of products as protection against contamination and counterfeiting.

Other markets that may utilize the ChromaID technology would be agriculture for fruit and vegetable ripeness, petrochemical for fluid analysis and verification or emissions analysis.

The medical applications for the technology may include noninvasive skin analysis for discovery of certain diseases or conditions based on the ChromaID of the individual’s skin.

### Commercialize the ChromaID Technology.

The current path to commercialization for those markets as stated above is to produce ChromaID generating, scanning and storing hardware and software components with a hardware form factor of a scanhead component device. These scanhead component modules can range in size from that of a pencil eraser to the size of a quarter coin depending upon the amount and type of light required for an accurate ChromaID profile.

These scanhead modules can then be incorporated into various products produced by third parties for the applications listed above. Along with the sale of the component parts there is revenue potential from licensing the technology to partners as is the case with SPP. SPP is currently developing a scanhead type device and has the rights to produce the components and market them in Asia. There may be other partnership opportunities in Europe and North America and those are being investigated.

Another avenue to revenue is database administration and management services. The ChromaID profile must be stored, managed, kept current or updated and readily accessible. In one model the database can be owned by the end customer but in the case of thousands of ChromaID profiles database management may be outsourced to Visualant or a third party provider. These database services can be a source of revenue on a per access transaction basis or on a monthly or annual subscription basis. By using a cell phone or other mobile technologies to access the database the actual storage location can be cloud based or local depending on the requirements of access, size of the database and security as defined by the customer.

### Complete work under the Joint Development Agreement with SPP.

### Accelerate business development in the United States and Japan.

We are coordinating the sales and marketing efforts of both Visualant and SPP to leverage market data and information and to focus on specific target verticals that have the greatest potential for early adoption. These include the aforementioned flat surface but also gaming in Asia. With the successful launch of the Cyclops6 scanhead at the JIMA instrument technology trade show in Japan we have become aware of a significantly expanded number of market opportunities from those who attended the show.

**Develop license and royalty producing opportunities and partners, including major companies in the US, Europe and Asia.**

**Develop our patent portfolio by continually extending the reach and application of our intellectual property.**

**Engineer and release a LAB KIT to enable potential customers to evaluate the ChromaID technology.**

### Launch an application product utilizing smartphone technology.

### Improve our operations, including the following:

Improve TransTech revenue with new product lines for distribution, including radio frequency ID tracking products and new document authentication products. Visualant and TransTech are working together to expand and promote our capabilities, products and services to their respective markets. TransTech has long standing business relationships in many sectors of the security industry and those relationships are being leveraged to introduce key industry personnel to the ChromaID technology. Visualant sales efforts are also uncovering additional markets and customers that are of interest and potential revenue to TransTech. Additionally, as the Visualant technology is incorporated into more products TransTech expects to be able to pair these products with others to offer expanded solutions for distribution into the security market space improving the profitability of TransTech and the company.

### Enhance our investor relation activities.

### PRIMARY RISKS AND UNCERTAINTIES

We are exposed to various risks related to our need for additional financing, the sale of significant numbers of our shares, a volatile market price for our common stock and any possible default under the note payable to Mr. Gingo. These risks and uncertainties are discussed in more detail below in Part II, Item 1A.

### RESULTS OF OPERATIONS

The following table presents certain consolidated statement of operations information and presentation of that data as a percentage of change from period-to-period.

(dollars in thousands)

|  | Three Months Ended March 31, 2013 | 2012 | $ Variance | % Variance |
| --- | ---: | ---: | ---: | ---: |
| Revenue | $2,218 | $1,899 | $319 | 16.8% |
| Cost of sales | 1,643 | 1,566 | 77 | 4.9% |
| Gross profit | 575 | 333 | 242 | 72.7% |
| Research and development expenses | 212 | 37 | 175 | (473.0)% |
| Selling, general and administrative expenses | 1,495 | 881 | 614 | (69.7)% |
| Operating loss | (1,132) | (585) | (547) | (93.5)% |
| Other income (expense): |  |  |  |  |
| Interest expense | (76) | (58) | (18) | (31.0)% |
| Other income | 7 | 5 | 2 | 40.0% |
| Loss on purchase of warrants and additional investment right | (1,150) | - | (1,150) | (100.0)% |
| Total other expense | (1,219) | (53) | (1,166) | (2,200.0)% |
| Loss before income taxes | (2,351) | (638) | (1,713) | (268.5)% |
| Income taxes - current benefit | (6) | (6) | - | 0.0% |
| Net loss | (2,345) | (632) | (1,713) | (271.0)% |
| Non-controlling interest | 2 | (1) | 3 | 300.0)% |
| Net loss attributable to Visualant, Inc. common shareholders | $(2,347) | $(631) | $(1,716) | (271.9)% |

### THREE MONTHS ENDED MARCH 31, 2013 COMPARED TO THE THREE MONTHS ENDED MARCH 31, 2012

SALES

Net revenue for the three months ended March 31, 2013 increased $319,000 to $2,218,000 as compared to $1,899,000 for the three months ended March 31, 2012. The increase was due to license revenue from SPP and improved sales at TransTech.

COST OF SALES

Cost of sales for the three months ended March 31, 2013 increased $77,000 to $1,643,000 as compared to $1,566,000 for the three months ended March 31, 2012. The increase was due to increased sales and product mix at TransTech.

RESEARCH AND DEVELOPMENT EXPENSES

Research and development expenses for the three months ended March 31, 2013 increased $175,000 to $212,000 as compared to $37,000 for the three months ended March 31, 2012. The increase was due to commercialization of Visualant’s ChromaID technology and the expenses incurred for the Joint Development Agreement with SPP.

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

Selling, general and administrative expenses for the three months ended March 31, 2013 increased $614,000 to $1,495,000 as compared to $881,000 for the three months ended March 31, 2012. The increase was due to increased business develop, public relations and investor relation activities.

During the three months ended March 31, 2013, we recorded non-cash expenses of $644,000.

The selling, general and administrative expenses consisted primarily of research and development expenses, employee and independent contractor expenses, overhead, equipment and depreciation, amortization of identifiable intangible assets and intellectual property, professional and consulting fees, investor relation, legal, patent, stock option and other general and administrative costs.

OTHER INCOME/EXPENSE

Other expense for the three months ended March 31, 2013 was $1,219,000 as compared to other expense of $53,000 for the three months ended March 31, 2012. The expenses for the three months ended March 31, 2013 included $1,150,000 loss on the purchase of warrants and additional investment right, $76,000 for interest expense, offset by $7,000 in other income. The other expense for the three months ended March 31, 2012 included interest expense of $58,000, offset by other income of $5,000.

NET LOSS

Net loss for the three months ended March 31, 2013 was $2,345,000 as compared to a net loss of $632,000 for the three months ended March 31, 2012 for the reasons discussed above. The net loss included non-cash expenses of $1,640,000.

(dollars in thousands)

|  | Six Months Ended March 31, 2013 | 2012 | $ Variance | % Variance |
| --- | ---: | ---: | ---: | ---: |
| Revenue | $4,273 | $3,712 | $561 | 15.1% |
| Cost of sales | 3,165 | 3,055 | 110 | 3.6% |
| Gross profit | 1,108 | 657 | 451 | 68.6% |
| Research and development expenses | 379 | 76 | 303 | (398.7)% |
| Selling, general and administrative expenses | 2,545 | 1,678 | 867 | (51.7)% |
| Operating loss | (1,816) | (1,097) | (719) | (65.5)% |
| Other income (expense): |  |  |  |  |
| Interest expense | (116) | (116) | - | 0.0% |
| Other income | 20 | 12 | 8 | 66.7% |
| Loss on purchase of warrants and additional investment right | (1,150) | - | (1,150) | (100.0)% |
| Total other expense | (1,246) | (104) | (1,142) | (1,098.1)% |
| Loss before income taxes | (3,062) | (1,201) | (1,861) | (155.0)% |
| Income taxes - current benefit | (15) | (14) | (1) | (7.1)% |
| Net loss | (3,047) | (1,187) | (1,860) | (156.7)% |
| Non-controlling interest | 8 | 4 | 4 | 100.0% |
| Net loss attributable to Visualant, Inc. common shareholders | $(3,055) | $(1,191) | $(1,864) | (156.5)% |

### SIX MONTHS ENDED MARCH 31, 2013 COMPARED TO THE SIX MONTHS ENDED MARCH 31, 2012

SALES

Net revenue for the six months ended March 31, 2013 increased $561,000 to $4,273,000 as compared to $3,712,000 for the six months ended March 31, 2012. The increase was due to license revenue from SPP and improved sales at TransTech.

COST OF SALES

Cost of sales for the six months ended March 31, 2013 increased $110,000 to $3,165,000 as compared to $3,055,000 for the six months ended March 31, 2012. The increase was due to increased sales and product mix at TransTech.

RESEARCH AND DEVELOPMENT EXPENSES

Research and development expenses for the six months ended March 31, 2013 increased $303,000 to $379,000 as compared to $76,000 for the six months ended March 31, 2012. The increase was due to commercialization of Visualant’s ChromaID technology and the expenses incurred for the Joint Development Agreement with SPP.

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

Selling, general and administrative expenses for the six months ended March 31, 2013 increased $867,000 to $2,545,000 as compared to $1,678,000 for the six months ended March 31, 2012. The increase was due to increased business develop, public relations and investor relation activities.

During the six months ended March 31, 2013, we recorded non-cash expenses of $790,000.

The selling, general and administrative expenses consisted primarily of research and development expenses, employee and independent contractor expenses, overhead, equipment and depreciation, amortization of identifiable intangible assets and intellectual property, professional and consulting fees, investor relation, legal, patent, stock option and other general and administrative costs.

OTHER INCOME/EXPENSE

Other expense for the six months ended March 31, 2013 was $1,246,000 as compared to other expense of $104,000 for the six months ended March 31, 2012. The expenses for the six months ended March 31, 2013 included $1,150,000 loss on the purchase of warrants and additional investment right, $116,000 for interest expense, offset by $20,000 in other income. The other expense for the six months ended March 31, 2012 included interest expense of $116,000, offset by other income of $12,000.

NET LOSS

Net loss for the six months ended March 31, 2013 was $3,047,000 as compared to a net loss of $1,187,000 for the six months ended March 31, 2012 for the reasons discussed above. The net loss included non-cash expenses of $1,640,000.

LIQUIDITY AND CAPITAL RESOURCES

We had cash of $15,000, a net working capital deficit of approximately $3.8 million and total indebtedness of $2.5 million as of March 31, 2013. Further, as of May 10, 2013, we have (i) $1 million due to James Gingo on June 8, 2013 to complete the acquisition of TransTech; (ii) $250,000 for the repurchase of the Gemini Master Fund, Ltd. warrant that was due on March 31, 2013; (iii) $300,000 if we purchase 4,000,000 shares from Ascendiant Capital Markets on or before May 31, 2013 pursuant to an Option Agreement; and (iv) $425,000 due under the AIR Termination Agreement to Gemini Master Fund, Ltd. on both June 30, 2013 and September 30, 2013.

We will need to obtain additional financing to implement our business plan and service our debt repayments. There can be no assurance that we will be able to secure funding, or that if such funding is available, the terms or conditions would be acceptable to us. If the Company is unable to obtain additional financing, we may need to restructure our operations, and divest all or a portion of our business.

Our recent efforts to generate additional liquidity, including through sales of our common stock, are described in more detail in the financial statement notes set forth in our Form 10-Q for the quarter ended December 31, 2012, which was filed with the SEC on February 11, 2013.

If we raise additional capital through borrowing or other debt financing, we will incur substantial interest expense. Sales of additional equity securities will dilute on a pro rata basis the percentage ownership of all holders of common stock. When we raise more equity capital in the future, it will result in substantial dilution to our current stockholders.

OPERATING ACTIVITIES

Net cash used in operating activities for the six months ended March 31, 2013 was $1,294,000. This amount was primarily related to a net loss of $3,047,000, an increase in inventory of $296,000 and a reduction in deferred revenue of $500,000, offset by depreciation and amortization and other non-cash expenses of $1,640,000 and an increase in accounts payable and accrued expenses of $723,000.

INVESTING ACTIVITIES

Net cash used in investing activities for the six months ended March 31, 2013 was $3,000. This amount was primarily related to capital expenditures of $15,000, offset by proceeds from the sale of equipment of $12,000.

FINANCING ACTIVITIES

Net cash provided by financing activities for the six months ended March 31, 2013 was $171,000. This amount was primarily related to proceeds from line of credit of $110,000, proceeds from the issuance of common stock of $100,000, offset by repayment of debt of $40,000.

Our contractual cash obligations as of March 31, 2013 are summarized in the table below:

| Contractual Cash Obligations | Total | Less Than 1 Year | 1-3 Years | 3-5 Years | Greater Than 5 Years |
| --- | ---: | ---: | ---: | ---: | ---: |
| Operating leases | $200,341 | $80,928 | $119,413 | $0 | $0 |
| Note payable | 2,549,012 | 2,546,093 | 2,919 | 0 | 0 |
| Capital expenditures | 525,000 | 125,000 | 150,000 | 125,000 | 125,000 |
| Convertible notes payable payments | 550,000 | 550,000 | 0 | 0 | 0 |
|  | $3,824,353 | $3,302,021 | $272,332 | $125,000 | $125,000 |

## Controls and procedures

As filed, 4,174 characters.

### MANAGEMENT'S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING

### a) Evaluation of Disclosure Controls and Procedures

We have adopted and maintain disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) that are designed to ensure that information required to be disclosed in our reports under the Exchange Act, is recorded, processed, summarized and reported within the time periods required under the SEC’s rules and forms and that the information is gathered and communicated to our management to allow for timely decisions regarding required disclosure.

As required by Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, our management conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures as of March 31, 2013. Our disclosure controls and procedures are designed to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and our management necessarily was required to apply its judgment in evaluating and implementing our disclosure controls and procedures. Based upon the evaluation described above, our management concluded that they believe that our disclosure controls and procedures were not effective, as of March 31, 2013, in providing reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management to allow timely decisions regarding required disclosures, and is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Management identified the weaknesses discussed below.

### Identified Material Weakness

A material weakness in our internal control over financial reporting is a control deficiency, or combination of control deficiencies, that results in more than a remote likelihood that a material misstatement of the financial statements will not be prevented or detected. Management identified material weaknesses during its assessment of internal controls over financial reporting as of March 31, 2013.

While we have an audit committee, we lack a financial expert. During 2013, the Board expects to appoint an additional independent Director to serve as Audit Committee Chairman who is an “audit committee financial expert” as defined by the Securities and Exchange Commission (“SEC”) and as adopted under the Sarbanes-Oxley Act of 2002.

### MANAGEMENT’S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we assessed the effectiveness of our internal control over financial reporting as of the end of the period covered by this report based on the framework in “Internal Control—Integrated Framework” issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on that assessment, our principal executive officer and principal financial officer concluded that our internal control over financial reporting were not effective to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of our financial statements for external purposes in accordance with United States generally accepted accounting principles.

The effectiveness of our internal control over financial reporting as of September 30, 2012 has not been audited by PMB Helin Donovan, LLP, an independent registered public accounting firm.

### CHANGES IN INTERNAL CONTROL

There has been no change in our internal control over financial reporting during the quarter ended March 31, 2013 that has materially affected or is likely to materially affect our internal control over financial reporting.

## Risk factors

As filed, 23,618 characters.

There are certain inherent risks which will have an effect on the Company’s development in the future and some of these risk factors are noted below but are not all encompassing since there may be others unknown to management at the present time which might have an impact in the future on the development of the Company.

WE WILL NEED ADDITIONAL FINANCING TO PAY OUR DEBTS AND SUPPORT OUR TECHNOLOGY DEVELOPMENT AND ONGOING OPERATIONS.

We had cash of $15,000, a net working capital deficit of approximately $3.8 million and total indebtedness of $2.5 million as of March 31, 2013. Further, as of May 10, 2013, we have (i) $1 million due to James Gingo on June 8, 2013 to complete the acquisition of TransTech; (ii) $250,000 for the repurchase of the Gemini Master Fund, Ltd. warrant that was due on March 31, 2013; (iii) $300,000 if we purchase of 4,000,000 shares from Ascendiant Capital Markets on or before May 31, 2013 pursuant to an Option Agreement; and (iv) $425,000 due under the AIR Termination Agreement to Gemini Master Fund, Ltd. on both June 30, 2013 and September 30, 2013.

We will need to obtain additional financing to implement our business plan and service our debt repayments. There can be no assurance that we will be able to secure funding, or that if such funding is available, the terms or conditions would be acceptable to us. If the Company is unable to obtain additional financing, we may need to restructure our operations, divest or lose our TransTech business and face litigation.

If we raise additional capital through borrowing or other debt financing, we will incur substantial interest expense. Sales of additional equity securities will dilute on a pro rata basis the percentage ownership of all holders of common stock. When we raise more equity capital in the future, it will result in substantial dilution to our current stockholders.

THE SALE OF A SIGNIFICANT NUMBER OF OUR SHARES OF COMMON STOCK COULD DEPRESS THE PRICE OF OUR COMMON STOCK.

Sales or issuances of a large number of shares of common stock in the public market or the perception that sales may occur could cause the market price of our common stock to decline. As of May 10, 2013, there were approximately 116.7 million shares of common stock issued and outstanding. Significant shares of common stock are held by our principal shareholders, other Company insiders and other large shareholders. As “affiliates” (as defined under Rule 144 of the Securities Act (“Rule 144”)) of the Company, our principal shareholders, other Company insiders and other large shareholders may only sell their shares of common stock in the public market pursuant to an effective registration statement or in compliance with Rule 144.

Some of the present shareholders have acquired shares at prices as low as $0.001 per share, whereas other shareholders have purchased their shares at prices ranging from $0.05 to $0.75 per share.

In addition, as of May 10, 2013, there are also options outstanding for the purchase of 11,005,000 common shares at a $0.131 average strike price, and warrants for the purchase of 2,857,051 common shares at a $0.235 average exercise price.

These options and warrants could result in further dilution to common stock holders and may affect the market price of the common stock.

FUTURE ISSUANCE OF COMMON STOCK RELATED TO FAILURE TO PAY AMOUNTS DUE TO REPURCHASE WARRANTS AND ADDITIONAL INVESTMENT RIGHTS MAY HAVE A DILUTING FACTOR ON EXISTING AND FUTURE SHAREHOLDERS.

On May 19, 2011, we entered into a Securities Purchase Agreement (“Agreement”) with Gemini Master Fund, Ltd. (“Gemini”) and Ascendiant Capital Partners, LLC (“Ascendiant”) (Gemini and Ascendiant are collectively referred to as the “Investors”), pursuant to which the Company issued $1.2 million in principal amount of 10% convertible debentures (the “Original Debentures”) which were due May 1, 2012. The due date of the Original Debentures was extended to September 30, 2012 pursuant to a First Amendment to the Agreement on March 12, 2012, and further extended to September 30, 2013 pursuant to a Second Amendment to the Agreement on August 16, 2012. In addition, we issued 5-year warrants to the Investors to collectively purchase 2,400,000 shares of our common stock. The purchase price for the debentures was 83.3% of the face amount, resulting in the Company receiving $1.0 million, less legal fees, placement agent fees and expenses as set forth below. The Agreement includes an additional investment right granted to the Investors, pursuant to which the Investors have the right at any time until September 30, 2013, to purchase up to $1.2 million in principal amount of additional debentures (the “Additional Debentures”) on the same terms and conditions as the Original Debentures, except that the conversion price on the Additional Debentures may have a higher floor. The conversion price on both the Original Debentures and the Additional Debentures are subject to a potential downward adjustment for any equity sales subsequent to the date of issuance. In conjunction with the purchase of the Additional Debentures, the Investors also have the right to purchase additional warrants. The above description is only a summary of the transactions with Gemini and Ascendiant and are subject to the full terms of the transaction agreements, copies of which were filed with the Company’s 10-K for the year ended September 30, 2012, as Exhibits 10.1 through 10.10.

On August 28, 2012, we entered into a Warrant Purchase Agreement with Gemini and acquired the Gemini Warrant covering the purchase of up to 1.8 million shares, subject to adjustment, by paying $250,000 on August 28, 2012 and agreeing to pay $250,000 on or before November 30, 2012.

On January 30, 2013, we and the Investors entered into the following additional agreements dated January 23, 2013 but made effective as of the date of their execution by the parties:

(1) Warrant Purchase Agreement between the Company and Ascendiant pursuant to which we agreed to repurchase the Ascendiant Warrant for a purchase price of $300,000, which amount was due in full on March 31, 2013. On April 26, 2013, we entered into an Option Agreement with Ascendiant pursuant to which we have the option to purchase from Ascendiant 4,000,000 shares of our common stock for a total purchase price of $300,000 If purchased by the Company, the shares are expected to be retired to treasury. The option must be exercised and payment for the shares must be made on or before May 31, 2013. Ascendiant was issued a total of 4,564,068 shares of common stock on April 26, 2013 as a result of Ascendiant’s cashless exercise of the Ascendiant warrant. We did not complete that purchase, thereby enabling Ascendiant to exercise the Ascendiant Warrant on April 26, 2013.

(2) Amendment to Warrant Purchase Agreement between the Company and Gemini extending the due date for payment of the balance of the purchase price, including accrued interest thereon, from November 30, 2012 to March 31, 2013. We are currently accruing interest at 18% on the $250,000 balance due to Gemini. The Company is currently in default on its payment obligation to Gemini, which entitles Gemini to exercise its warrant, which could result in substantial additional dilution to the Company’s shareholders.

(3) AIR Termination Agreement between the Company and Gemini pursuant to which the Company acquired all additional investment rights (“AIR”) of Gemini and Ascendiant under the Securities Purchase Agreement for the sum of $850,000, to be paid pursuant to the terms of a promissory note executed by the Company for the principal amount of $850,000. The promissory note is payable in two installments of $425,000 each, together with accrued interest thereon at the rate of 5% per annum, due on June 30, 2013 and September 30, 2013. If the payments are not made, the Company owes 120% of the balance due plus interest.

#### Conversion of Existing Convertible Debentures

On January 24, 2013, Gemini converted $300,000 of principal and $50,630 of accrued interest on its Debenture into 7,012,603 shares of common stock at a conversion price of $.05 per share.

On January 24, 2013, Ascendiant converted $50,000 of principal and $8,438 of accrued interest on its Debenture into 1,168,767 shares of common stock at a conversion price of $.05 per share.

On January 28, 2013, Gemini converted $300,000 of principal and $50,959 of accrued interest on its Debenture into 7,019,178 shares of common stock at a conversion price of $.05 per share.

Following these conversions, as of January 28, 2013, the outstanding principal amounts and all accrued interest on the Debentures of both Gemini and Ascendiant have been fully converted.

The conversion of the convertible notes payable resulted in substantial dilution of the value of the common shares for all shareholders. The failure to pay the $250,000 for the repurchase of the Gemini warrant due on March 31, 2013 may result in substantial additional dilution of the value of the common shares for all shareholders. The exercise of the Ascendiant Warrant on April 26, 2013, resulted in substantial dilution, which the Company may be able to mitigate if it is able to raise the money to exercise the Option Agreement to repurchase 4,000,000 of the shares issued to Ascendiant on exercise of the Ascendiant Warrant.

RISKS ASSOCIATED WITH A POSSIBLE DEFAULT UNDER THE NOTE DUE TO MR. GINGO.

The Company acquired its 100% interest in TransTech by issuing a Promissory Note on June 8, 2010 (“Note”) to James Gingo, the President of TransTech, in the amount of $2,300,000, plus interest at the rate of three and one-half percent (3.5%) per annum from the date of the Note. The Note is secured by a security interest in the stock and assets of TransTech. Mr. Gingo has the following rights (in addition to all other rights and remedies at law or in equity or otherwise) in case of a possible default, which is not cured within ten days:

(a) Declare the entire balance of the Note immediately due and payable;

(b) Register in the Secured Party’s name any or all of the TTS Shares;

(c) Exercise the Secured Party’s proxy rights with respect to all or a portion of the TTS Shares, in which event the Pledgor agrees to deliver promptly to the Secured Party further evidence of the grant of the proxy in any form requested by the Secured Party; and

(d) Sell or otherwise dispose of the TTS Shares.

As of March 31, 2013, the remaining balance of $1,000,000 on the Note and interest shall be paid to Seller on the earlier of June 8, 2013 or on the closing of $7,500,000 or more in aggregate financing (whether debt, equity or some combination thereof) after the closing date.

In the case of a possible default, we risk losing ownership of TransTech and face possible litigation with Mr. Gingo.

RISKS ASSOCIATED WITH EQUITY LINE OF CREDIT WITH ASCENDIANT

The Securities Purchase Agreement dated June 17, 2011 with Ascendiant will terminate if our common stock is not listed on one of several specified trading markets (which include the OTCBB and Pink Sheets, among others), if we file protection from our creditors, or if a Registration Statement on Form S-1 or S-3 is not effective.

As of May 10, 2013, the Company has issued 6,358,933 shares for $483,141, or an average of $.076 per share, under the Securities Purchase Agreement with Ascendiant. The Company has registered a total of 10,285,714 shares of common stock for resale by Ascendiant.

Our equity line of credit with Ascendiant remains outstanding, with available credit of $2,516,859. We have no current intention to utilize this line of credit, which expires August 29, 2013.

WE MAY ENGAGE IN ACQUISITIONS, MERGERS, STRATEGIC ALLIANCES, JOINT VENTURES AND DIVESTITURES THAT COULD RESULT IN FINANCIAL RESULTS THAT ARE DIFFERENT THAN EXPECTED.

In the normal course of business, we engage in discussions relating to possible acquisitions, equity investments, mergers, strategic alliances, joint ventures and divestitures. Such transactions are accompanied by a number of risks, including:

\- Use of significant amounts of cash;

\- Potentially dilutive issuances of equity securities on potentially unfavorable terms;

\- Incurrence of debt on potentially unfavorable terms as well as impairment expenses related to goodwill and amortization expenses related to other intangible assets; and

\- The possibility that we may pay too much cash or issue too many of our shares as the purchase price for an acquisition relative to the economic benefits that we ultimately derive from such acquisition.

The process of integrating any acquisition may create unforeseen operating difficulties and expenditures. The areas where we may face difficulties include:

\- Diversion of management time, during the period of negotiation through closing and after closing, from its focus on operating the businesses to issues of integration;

\- Decline in employee morale and retention issues resulting from changes in compensation, reporting relationships, future prospects or the direction of the business;

\- The need to integrate each Company's accounting, management information, human resource and other administrative systems to permit effective management, and the lack of control if such integration is delayed or not implemented;

\- The need to implement controls, procedures and policies appropriate for a public Company that may not have been in place in private companies, prior to acquisition;

\- The need to incorporate acquired technology, content or rights into our products and any expenses related to such integration; and

\- The need to successfully develop any acquired in-process technology to realize any value capitalized as intangible assets.

From time to time, we have also engaged in discussions with candidates regarding the potential acquisitions of our product lines, technologies and businesses. If a divestiture such as this does occur, we cannot be certain that our business, operating results and financial condition will not be materially and adversely affected. A successful divestiture depends on various factors, including our ability to:

\- Effectively transfer liabilities, contracts, facilities and employees to any purchaser;

\- Identify and separate the intellectual property to be divested from the intellectual property that we wish to retain;

\- Reduce fixed costs previously associated with the divested assets or business; and

\- Collect the proceeds from any divestitures.

In addition, if customers of the divested business do not receive the same level of service from the new owners, this may adversely affect our other businesses to the extent that these customers also purchase other products offered by us. All of these efforts require varying levels of management resources, which may divert our attention from other business operations.

If we do not realize the expected benefits or synergies of any divestiture transaction, our consolidated financial position, results of operations, cash flows and stock price could be negatively impacted.

WE MAY INCUR LOSSES IN THE FUTURE.

We have experienced net losses since inception. As of March 31, 2013, we had an accumulated deficit of $17 million. There can be no assurance that we will achieve or maintain profitability.

THE MARKET PRICE OF OUR COMMON STOCK HAS BEEN AND MAY CONTINUE TO BE VOLATILE.

The market price of our common stock has been and is likely in the future to be volatile. Our common stock price may fluctuate in response to factors such as:

- Announcements by us regarding liquidity, significant acquisitions, equity investments and divestitures, strategic relationships, addition or loss of significant customers and contracts, capital expenditure commitments, loan, note payable and agreement defaults, loss of our subsidiaries and impairment of assets;
- Issuance of convertible or equity securities for general or merger and acquisition purposes;
- Issuance or repayment of debt, accounts payable or convertible debt for general or merger and acquisition purposes;
- Sale of a significant number of shares of our common stock by shareholders;
- General market and economic conditions;
- Quarterly variations in our operating results;
- Investor and public relation activities;
- Announcements of technological innovations;
- New product introductions by us or our competitors;
- Competitive activities; and
- Additions or departures of key personnel.

These broad market and industry factors may have a material adverse effect on the market price of our common stock, regardless of our actual operating performance. These factors could have a material adverse effect on our business, financial condition and results of operations.

FUTURE ISSUANCE OF STOCK OPTIONS, WARRANTS AND/OR RIGHTS MAY HAVE A DILUTING FACTOR ON EXISTING AND FUTURE SHAREHOLDERS.

The grant and exercise of stock options, warrants or rights to be issued in the future will likely result in a dilution of the value of our common shares for all shareholders. We have established a Combined Incentive and Non-Qualified Stock Option Plan and may in the future issue further stock options to officers, directors and consultants, which will dilute the interest of the existing and future shareholders. Dilution of the value of the common shares will likely result from such option and/or stock grants, which in turn could adversely affect the market price of our common stock.

TRADING IN THE COMPANY’S STOCK MAY BE RESTRICTED BY BLUE SKY ELIGIBILITY AND THE SEC’S PENNY STOCK REGULATIONS.

The SEC has adopted regulations which generally define "penny stock" to be any equity security that has a market price (as defined) less than $5.00 per share or an exercise price of less than $5.00 per share, subject to certain exceptions. Under the penny stock rules, additional sales practice requirements are imposed on broker-dealers who sell to persons other than established customers and "accredited investors." The term "accredited investor" refers generally to institutions with assets in excess of $5,000,000 or individuals with a net worth in excess of $1,000,000 or annual income exceeding $200,000 or $300,000 jointly with their spouse. The penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document in a form prepared by the SEC which provides information about penny stocks and the nature and level of risks in the penny stock market. The broker-dealer also must provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson in the transaction, and monthly account statements showing the market value of each penny stock held in the customer's account. The bid and offer quotations, and the broker-dealer and salesperson compensation information, must be given to the customer orally or in writing prior to effecting the transaction and must be given to the customer in writing before or with the customer's confirmation. In addition, the penny stock rules require that prior to a transaction in a penny stock not otherwise exempt from these rules, the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser's written agreement to the transaction. These disclosure requirements may have the effect of reducing the level of trading activity in the secondary market for the stock that is subject to broker-dealers to trade in the Company’s securities.

The penny stock rules may discourage investor interest in and limit the marketability of, the Company’s common stock.

CONFLICT OF INTEREST.

Some of the directors of the Company are also directors and officers of other companies, and conflicts of interest may arise between their duties as directors of the Company and as directors and officers of other companies. These factors could have a material adverse effect on our business, financial condition and results of operations.

WE ARE DEPENDENT ON KEY PERSONNEL.

Our success depends to a significant degree upon the continued contributions of key management and other personnel, some of whom could be difficult to replace. We do not maintain key man life insurance covering certain of our officers. Our success will depend on the performance of our officers, our ability to retain and motivate our officers, our ability to integrate new officers into our operations and the ability of all personnel to work together effectively as a team. Other than the James Gingo Employment Agreement which expires June 8, 2013, our officers do not have employment agreements. Our failure to retain and recruit officers and other key personnel could have a material adverse effect on our business, financial condition and results of operations.

WE HAVE LIMITED INSURANCE.

We have limited director and officer insurance and commercial insurance policies. Any significant claims would have a material adverse effect on our business, financial condition and results of operations.

OUR JOINT DEVELOPMENT AGREEMENT WITH SUMITOMO PRECISION PRODUCTS CO. LTD IS IMPORTANT TO OUR OPERATIONS AND IS SUBJECT TO EXPIRATION.

On May 31, 2012, the Company entered into a Joint Research and Product Development Agreement (the “Joint Development Agreement”) with SPP for the commercialization of Visualant’s ChromaID technology. A copy of the Joint Development Agreement was filed by the Company with its Form 8-K filed June 4, 2012. The Joint Development Agreement was extended to December 31, 2013. We have certain product development responsibilities under the Joint Development Agreement. In addition, the ownership of technology under the Joint Development Agreement is discussed in our Form 8-K filed June 4, 2012.

The failure to operate in accordance with the Joint Development Agreement could result in the agreement not being renewed.

WE NEED TO CONTINUE AS A GOING CONCERN IF OUR BUSINESS IS TO SUCCEED.

Our financial statements and notes for the three months ended March 31, 2013 indicates that there are a number of factors that raise substantial doubt about our ability to continue as a going concern. Such factors identified in the report result from net losses, negative working capital and the need for additional financing to implement our business plan and service our debt repayments. If we are not able to continue as a going concern, it is likely investors will lose their investments.

WE MAY BE UNABLE TO PROTECT OUR IP RIGHTS, WHICH WOULD HARM OUR BUSINESS, FINANCIAL CONDITION AND OPERATING RESULTS.

We rely on a combination of patent, trademark, and trade secret laws, confidentiality procedures and licensing arrangements to protect our IP rights.

There can be no assurance that:

- any of our existing patents will continue to be held valid, if challenged;
- patents will be issued for any of our pending applications;
- any claims allowed from existing or pending patents will have sufficient scope or strength to protect us;
- our patents will be issued in the primary countries where our products are sold in order to protect our rights and potential commercial advantage; or
- any of our products or technologies do not infringe on the patents of other companies.

If we are enjoined from selling our products, or if we are required to develop new technologies or pay significant monetary damages or are required to make substantial royalty payments, our business and results of operations would be harmed.

Filed May 10, 2013.
Source: SEC EDGAR, the filing index for accession 0001199835-13-000231. Last ingested by Listed: Nov 6, 2026, 12:33 ET. No prices; not investment advice.
